Moderna, Inc. — Director's Dealing 2025

May 1, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2025-04-30

Reporting Person: Hussain Abbas (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-04-30	Common Stock	M	892	—	Acquired	892	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-04-30	Restricted Stock Units	$	M	892	Disposed		Common Stock (892)	Direct
2025-04-30	Restricted Stock Units	$	A	16233	Acquired		Common Stock (16233)	Direct

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: The shares subject to this restricted stock unit award vested in full on April 30, 2025.

F3: The shares subject to this restricted stock unit award will vest in full on the earlier of April 30, 2026, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.